MLD according to the WHO classification in AML has no correlation with age and no independent prognosis relevance analyzed in 1766 patients

Klinikum Nürnberg, Medizinische Klinik 5, Hämatologie/Onkologie, Nürnberg, Germany.
Blood (Impact Factor: 10.45). 02/2008; 111(4):1855-61. DOI: 10.1182/blood-2007-08-101162
Source: PubMed


Between February 1996 and December 2004, the German Leukemia Study Initiative registered 1766 consecutive patients for the acute myeloid leukemia (AML) 96 study, all of whom were diagnosed by central cytomorphology according to the French-American-British (FAB) and the new World Health Organization (WHO) classification. We focused our analysis on the prognostic impact of multilineage dysplasia (MLD) as a new parameter of the WHO classification for AML. We could not confirm the WHO statement that MLD occurs most frequently in older individuals, but we confirmed that MLD is often associated with an unfavorable cytogenetic profile (P < .001). In 1332 individuals receiving intensive AML therapy presence of MLD was negatively correlated with complete remission (P = .001) in univariate, but not in multivariate, analysis. Multivariate analysis of either event-free or overall survival again failed to show an independent prognostic significance of MLD besides age, cytogenetics, and, in part, NPM1/FLT3-ITD mutations. Our data support a reassessment of the WHO classification in the light of a more biologic understanding of AML. This study is registered at as #NCT00180115.

Download full-text


Available from: Pascheberg Ulrich
  • [Show abstract] [Hide abstract]
    ABSTRACT: The principles according to modern views and practical needs of classification of acute leukemia are discussed on the basis of morphological properties of the leukemic cells after panoptic staining and of their cytochemical reactions. This form of classification gives some indications for the choice of treatment and for the prognosis. It is also the permission for the evaluation of therapeutic results, as are the other factors relevant for the prognosis.
    No preview · Article · Feb 1970 · Österreichische Zeitschrift für Erforschung und Bekämpfung der Krebskrankheit
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human nucleophosmin (NPM1), an essential gene, encodes for a ubiquitously expressed protein that plays multiple functions, including stabilization of the Arf tumor suppressor protein, regulation of ribosome biogenesis, and control of centrosome duplication. Although NPM1 constantly shuttles between nucleus and cytoplasm, it resides mainly in the nucleolus. The NPM1 gene is mutated in about one third of adult acute myeloid leukemia (AML) cases. Despite molecular heterogeneity (about 40 variants have been identified to date), all NPM1 mutations determine common alterations at the C-terminus of NPM1 mutant proteins (changes of tryptophans 288 and 290, or 290 alone, and creation of an additional nuclear export signal motif), which cause aberrant NPM1 mutant expression in the cytoplasm of leukemic cells. Acute myeloid leukemia with mutated NPM1 shows distinctive biologic and clinical features, including unique gene expression profile, high frequency of FMS-like tyrosine kinase (FLT3)-internal tandem duplication (ITD), increased incidence in adults and women, wide morphologic spectrum, CD34 negativity, multilineage involvement, and good response to induction therapy. Discovery of mutated NPM1 in AML has already had major diagnostic and clinical implications. Immunohistochemical detection of cytoplasmic nucleophosmin, which is fully predictive of NPM1 mutations, might help rationalize cytogenetic/molecular studies and facilitate genetic classification of AML. Within the heterogeneous category of AML with normal karyotype, NPM1 mutations in the absence of FLT3-ITD identify a subset of patients with favorable prognosis. Because of their stability, NPM1 mutations might become a new tool for monitoring minimal residual disease in about 30% of patients with AML. Understanding how mutations in NPM1 promote leukemia could provide the rationale for the development of targeted therapies.
    No preview · Article · Aug 2008 · Clinical Leukemia
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sowohl die akuten Leukämien als auch die chronischen Leukämien sind sehr heterogene Krankheiten, welche sich auf der Grundlage ihrer morphologischen, immunologischen und genetischen Eigenschaften in eine Vielzahl von Subtypen gliedern lassen. Nur eine Kombination verschiedener Methoden der hämatologischen Diagnostik ist in der Lage, diese Subtypen korrekt zu erfassen und dem jeweiligen prognostischen Profil zuzuordnen. Dabei wirken die Zytomorphologie, die Zyto- und Molekulargenetik sowie die Immunphänotypisierung mit der Multiparameter-Durchflusszytometrie zusammen. Moderne Klassifikationssysteme wie die WHO-Klassifikation aus dem Jahre 2001 beziehen all diese Methoden ein, stützen sich aber auch auf bereits länger etablierte, vorwiegend morphologisch begründete Systeme wie die FAB-Klassifikation der akuten myeloischen Leukämie (AML). Angesichts der kontinuierlichen Erweiterung des Spektrums bekannter genetischer Marker und aufgrund tieferer Einsichten in die Leukämogenese werden auch in Zukunft immer wieder Revisionen der gängigen Klassifikationssysteme notwendig sein. Dies kann am Beispiel der AML verdeutlicht werden, bei welcher die Identifizierung der Nucleophosmin-(NPM1-)Mutation bei der Mehrheit der Patienten mit normalem Karyotyp bald eine eigenständige Kategorie für diese Subgruppe erfordern wird. Bei der chronischen lymphatischen Leukämie (CLL) gelingt auf molekularer Basis eine Risikostratifizierung auf der Basis des Mutationsstatus der Gene, welche für die Schwerketten der Immunglobuline kodieren. Somit sind alle Klassifikationssysteme für Leukämien einem ständigen Wandel unterworfen. Diese Übersicht stellt dar, welche Parameter derzeit zur Klassifikation der akuten und chronischen Leukämien relevant sind, welcher diagnostischen Methoden es bedarf, um die notwendigen Informationen bei den jeweiligen Entitäten zu liefern, und welche aktuellen Erkenntnisse richtungweisend für künftige Klassifikationssysteme sind. Acute and chronic leukemias represent heterogeneous disorders which are divided in a variety of subtypes based on morphological, immunologic, and genetic characteristics. A combination of diverse diagnostic methods is necessary to perform a correct classification of these subtypes and to correlate them to the respective prognostic profiles: cytomorphology, cyto- and molecular genetics, and immunophenotyping by multiparameter flow cytometry. Modern classification systems such as the WHO classification (2001) integrate all these methods, although they are based on previous classification systems using preferentially cytomorphological criteria such as the FAB classification of acute myeloid leukemia (AML). However, in consideration of the continuous expansion of the spectrum of known genetic markers and due to deeper insights into the mechanisms of leukemogenesis, these classification systems need to be revised already in the near future. This can be illustrated by the recent detection of the nucleophosmin (NPM1) mutations in the majority of AML patients with a normal karyotype which might soon be followed by an own category for this subgroup within a revised WHO classification. In chronic lymphatic leukemia (CLL) the definition of the molecular mutation status of the genes coding for the immunoglobulin heavy chain by molecular methods was able to improve risk stratification. Thus, all systems for leukemia classification are in continuous change. This review presents a survey of the parameters which are relevant for the classification of the acute and chronic leukemias, of the diagnostic methods which are essential to guarantee the relevant information, and, finally, of recent results of leukemia research which might influence future classification systems.
    No preview · Article · Aug 2008 · Onkopipeline
Show more